You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Article info

Article menu

Download PDFPDF

Immune cell therapies and immune cell engineering
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)

Authors

  • Marc Wehrli Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Kathleen Gallagher Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Yi-Bin Chen Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Mark B Leick Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Steven L McAfee Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Areej R El-Jawahri Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Zachariah DeFilipp Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Nora Horick Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Paul O'Donnell Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Thomas Spitzer Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Bimal Dey Harvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Daniella Cook Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Michael Trailor Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Kevin Lindell Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Marcela V Maus Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  • Matthew J Frigault Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USAHarvard Medical School, Boston, MA, USAHematopoietic Cell Transplant & Cell Therapy Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Marcela V Maus; mvmaus{at}mgh.harvard.edu
View Full Text

Citation

Wehrli M, Gallagher K, Chen Y, et al
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
Journal for ImmunoTherapy of Cancer 2022;10:e003847. doi: 10.1136/jitc-2021-003847

Publication history

  • Accepted December 17, 2021
  • First published January 7, 2022.
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.